XML 66 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary Of Significant Accounting Policies - Addtional Information (Detail) (USD $)
 1 Months Ended 12 Months Ended
Dec. 31, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Jun. 30, 2012
Significant Accounting Policies [Line Items]            
Accrued license payments - related party $ 100,000us-gaap_DueToRelatedPartiesCurrent $ 100,000us-gaap_DueToRelatedPartiesCurrent $ 100,000us-gaap_DueToRelatedPartiesCurrent      
Accrued expense - related party 67,050bpth_AccruedLiabilitiesRelatedPartiesCurrent 67,050bpth_AccruedLiabilitiesRelatedPartiesCurrent 52,050bpth_AccruedLiabilitiesRelatedPartiesCurrent      
Other Intangible Assets, Net 1,250,893us-gaap_OtherIntangibleAssetsNet 1,250,893us-gaap_OtherIntangibleAssetsNet 1,411,518us-gaap_OtherIntangibleAssetsNet 1,572,143us-gaap_OtherIntangibleAssetsNet    
Other Finite-Lived Intangible Assets, Gross 2,500,374us-gaap_OtherFiniteLivedIntangibleAssetsGross 2,500,374us-gaap_OtherFiniteLivedIntangibleAssetsGross 2,500,374us-gaap_OtherFiniteLivedIntangibleAssetsGross 2,500,374us-gaap_OtherFiniteLivedIntangibleAssetsGross    
Amortization of Intangible Assets   1,249,481us-gaap_AmortizationOfIntangibleAssets 1,088,856us-gaap_AmortizationOfIntangibleAssets 928,231us-gaap_AmortizationOfIntangibleAssets    
Clinical Trial Expense 193,640bpth_ClinicalTrialExpense          
Research and Development 1,630,439us-gaap_ResearchAndDevelopmentExpense 1,630,439us-gaap_ResearchAndDevelopmentExpense [1] 1,518,885us-gaap_ResearchAndDevelopmentExpense [1] 1,132,712us-gaap_ResearchAndDevelopmentExpense [1]    
Cash 13,858,798us-gaap_Cash 13,858,798us-gaap_Cash 3,551,832us-gaap_Cash 534,046us-gaap_Cash 952,252us-gaap_Cash  
Depreciation   10,284us-gaap_Depreciation 0us-gaap_Depreciation 0us-gaap_Depreciation    
Technology Amortisation Period 15 years          
Technology Amortisation Monthly 160,000bpth_TechnologyAmortisationMonthly 160,000bpth_TechnologyAmortisationMonthly        
Research and Development Costs Expenses 1,630,439bpth_ResearchAndDevelopmentCostsExpenses          
Amortization 160,625us-gaap_AdjustmentForAmortization 160,625us-gaap_AdjustmentForAmortization 160,625us-gaap_AdjustmentForAmortization 185,271us-gaap_AdjustmentForAmortization    
Drug Storage And Transportation 11,965bpth_DrugStorageAndTransportation          
Advisory Services 90,337bpth_AdvisoryServices          
Preclinical Studies 40,520bpth_PreclinicalStudies          
Allocated Share-Based Compensation Expense 83,139us-gaap_AllocatedShareBasedCompensationExpense          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   4,734,861us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 4,848,298us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 3,296,354us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount    
Warrant            
Significant Accounting Policies [Line Items]            
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   10,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_WarrantMember		 10,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_WarrantMember		 10,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_WarrantMember		    
Furniture            
Significant Accounting Policies [Line Items]            
Property, Plant and Equipment, Useful Life   3 years        
Fixtures            
Significant Accounting Policies [Line Items]            
Property, Plant and Equipment, Useful Life   3 years        
Equipment            
Significant Accounting Policies [Line Items]            
Property, Plant and Equipment, Useful Life   3 years        
Research and Development Expense            
Significant Accounting Policies [Line Items]            
Clinical Trial Expense 115,450bpth_ClinicalTrialExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember		          
Other Expense            
Significant Accounting Policies [Line Items]            
Research and Development 29,189us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_OtherExpenseMember		          
Drug Material Manufactured            
Significant Accounting Policies [Line Items]            
Research and Development 729,031us-gaap_ResearchAndDevelopmentExpense
/ dei_LegalEntityAxis
= bpth_DrugMaterialManufacturedMember		          
Manufacturing Development and Product Testing            
Significant Accounting Policies [Line Items]            
Research and Development 291,993us-gaap_ResearchAndDevelopmentExpense
/ dei_LegalEntityAxis
= bpth_ManufacturingDevelopmentAndProductTestingMember		          
Jp Morgan Chase Bank            
Significant Accounting Policies [Line Items]            
Cash, FDIC Insured Amount 13,608,798us-gaap_CashFDICInsuredAmount
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_JpMorganChaseBankMember		 13,608,798us-gaap_CashFDICInsuredAmount
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_JpMorganChaseBankMember		 3,301,832us-gaap_CashFDICInsuredAmount
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_JpMorganChaseBankMember		 284,046us-gaap_CashFDICInsuredAmount
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_JpMorganChaseBankMember		    
Federal Deposit Insurance   250,000bpth_FederalDepositInsurance
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_JpMorganChaseBankMember		        
Md Anderson            
Significant Accounting Policies [Line Items]            
License Expenses     63,655bpth_LicenseExpenses
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
Sirna Patent Technology License     13,655bpth_SirnaPatentTechnologyLicense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
License Maintenance Fees     50,000bpth_LicenseMaintenanceFees
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
Technology Cost Paid In cash         836,207bpth_TechnologyCostPaidInCash
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 836,207bpth_TechnologyCostPaidInCash
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember
Technology Cost Paid In Shares         3,138,889bpth_TechnologyCostPaidInShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 3,138,889bpth_TechnologyCostPaidInShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember
Technology Cost Paid In Shares Value         2,354,167bpth_TechnologyCostPaidInSharesValue
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 2,354,167bpth_TechnologyCostPaidInSharesValue
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember
Technology Impairment Charge         690,000bpth_TechnologyImpairmentCharge
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 690,000bpth_TechnologyImpairmentCharge
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember
Md Anderson | Research and Development Expense            
Significant Accounting Policies [Line Items]            
Cash paid to MD Anderson Cancer Center for expenses   196,661us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 115,705us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
Accrued license payments - related party 100,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 100,000us-gaap_DueToRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		        
Accrued expense - related party 115,450bpth_AccruedLiabilitiesRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 115,450bpth_AccruedLiabilitiesRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 115,705bpth_AccruedLiabilitiesRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
License Expenses   50,000bpth_LicenseExpenses
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		        
Clinical Trial Expense   67,050bpth_ClinicalTrialExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		 52,050bpth_ClinicalTrialExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_MdAndersonMember		      
Related Party            
Significant Accounting Policies [Line Items]            
Research and Development 196,661us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		 196,661us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		 [2] 115,705us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		 [2] 463,870us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		 [2]    
Related Party | Research and Development Expense            
Significant Accounting Policies [Line Items]            
Accrued expense - related party       26,000bpth_AccruedLiabilitiesRelatedPartiesCurrent
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		    
Sirna Patent Technology License 31,211bpth_SirnaPatentTechnologyLicense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		 31,211bpth_SirnaPatentTechnologyLicense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		   8,582bpth_SirnaPatentTechnologyLicense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		    
License Maintenance Fees 50,000bpth_LicenseMaintenanceFees
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		          
Research and Development 196,661us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		     463,870us-gaap_ResearchAndDevelopmentExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		    
Annual Maintenance Fee       $ 100,000bpth_AnnualMaintenanceFee
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_ResearchAndDevelopmentExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= bpth_RelatedPartyMember		    
[1] Research and development expense includes stock option expense of $83,139, $32,879 and $53,645 for the years ending 12/31/2014, 12/31/2013 and 12/31/2012, respectively. Research and development expense also includes amortization expense of $160,625 for the years ending 12/31/2014 and 12/31/2013, and $185,271 for the year ending 12/31/2012.
[2] Includes $345,000 technology impairment charge for the year ending 12/31/2012.